The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.
Neurokin will perform its development programs either through VC financing or through a partnership with a Pharma interested in bringing them further into the clinic. For investment opportunities please use the contact information you can find here.
Current Investors include:
CEA Valorisation
http://www.cea-valorisation.com
CEA Valorisation provides seed/early stage investment to high potential start-ups either commercializing innovations developped at CEA or doing business in the technology sectors where CEA is active in R&D (i.e. micro and nano technologies, new energy technologies, new materials, biotech and medtech, systems and softwares...).
Inserm Transfert Initiative
Inserm Transfer Initiative is new innovative seed venture capital company created to invest at the pre-seed and seed stage of life-science companies.
